EMA Marketing Authorization of New Drugs in August 2025

Shots: The EMA’s CHMP has granted approvals to 1 Biologic and 3 new chemical entities in August 2025, leading to treatments for patients and advances in the healthcare industry The major highlighted drug was Gilead’s Yeytuo has Secured the EC’s Approval for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV PharmaShots has compiled a list of 4…

ByDipanshu DixitSeptember 16, 2025

VIEWPOINTS

Jazz Pharmaceuticals at ASCO 2025: Robert lannone in an Illuminating Conversation with PharmaShots

Shots: Jazz Pharmaceuticals and partners presented seven abstracts from their oncology development program at ASCO 2025 Robert Iannone, EVP, Global Head of Research and Development, and Chief Medical Officer at Jazz Pharmaceuticals, in an engaging discussion with PharmaShots, shared insights from the P-III IMforte trial assessing Zepzelca plus atezolizumab in first-line maintenance treatment for Extensive…

BySaurabh ChaubeyAugust 25, 2025

INSIGHTS+

EMA Marketing Authorization of New Drugs in July 2025

Shots: The EMA’s CHMP has granted positive opinions and approvals to 3 Biologics and 10 new chemical entities in July 2025, leading to treatments for patients and advances in the healthcare industry The major highlighted drug was Roche’s Itovebi Secures the EC’s Approval for PIK3CA-mutated Breast Cancer PharmaShots has compiled a list of 13 drugs…

ByDipanshu DixitAugust 19, 2025

THOUGHTSPOT

All-On-4 Dental Implants: A Breakthrough In Full Smile Restoration

A complete smile can improve how a person looks, speaks, and eats. Losing most or all teeth can make everyday life harder. Dentures are one option, but many people find them uncomfortable or unstable. They might slip while talking or eating. All-on-4 dental implants offer a better way to bring back a full smile with…

ByNatalie PierceJuly 2, 2025

INSIGHTS+

The US FDA New Drug Approvals in May 2025

Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of May 2025 The US FDA has approved a total of 3 new drugs, including 2 new molecular entities and 1 Biologic leading to the treatment of patients and advances in the healthcare industry The major highlighted drug was AbbVie’s Emrelis securing…

ByDipanshu DixitJune 10, 2025

INSIGHTS+

The US FDA New Drug Approvals in April 2025

Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of April 2025 The US FDA has approved a total of 3 new drug including 1 new molecular entity and 2 Biologics leading to the treatment of patients and advances in the healthcare industry The major highlighted drug was Johnson & Johnson’s…

ByDipanshu DixitMay 13, 2025

INSIGHTS+

Disease of the Month – Myocardial infarction (MI)

Shots: Myocardial infarction (MI), colloquially known as a heart attack, occurs when blood flow to the heart is severely reduced or blocked, causing tissue damage or mortality due to lack of oxygen PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types,…

ByDipanshu DixitApril 30, 2025

INSIGHTS+

EMA Marketing Authorization of New Drugs in March 2025

Shots: The EMA’s CHMP has granted positive opinions and approvals to 2 Biologics and 1 New Chemical Entity in March 2025, leading to treatments for patients and advances in the healthcare industry The major highlighted drugs were Merck’s Capvaxive to treat invasive pneumococcal disease PharmaShots has compiled a list of 3 drugs that have been…

ByDipanshu DixitApril 22, 2025

INSIGHTS+

The US FDA New Drug Approvals in March 2025

Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of March 2025 The US FDA has approved a total of 2 new drug including 2 new molecular entities leading to the treatment of patients and advances in the healthcare industry The major highlighted drug was GSK’s Blujepa securing approval for treating…

ByDipanshu DixitApril 15, 2025

INSIGHTS+

Disease of the Month – Dry age-related macular degeneration (dAMD)

Shots: Dry age-related macular degeneration (dAMD) is a common eye disorder that gradually damages the macula, the central part of the retina, responsible for sharp vision Our Disease of the Month report covers epidemiology, market size, current management strategies, emerging therapeutic options, and the role of patient advocacy groups. Additionally, we highlight the key industry…

ByDipanshu DixitDecember 24, 2024

EMA Marketing Authorization of New Drugs in August 2025

Jazz Pharmaceuticals at ASCO 2025: Robert lannone in an Illuminating Conversation with PharmaShots

EMA Marketing Authorization of New Drugs in July 2025

All-On-4 Dental Implants: A Breakthrough In Full Smile Restoration

The US FDA New Drug Approvals in May 2025

The US FDA New Drug Approvals in April 2025

Disease of the Month – Myocardial infarction (MI)

EMA Marketing Authorization of New Drugs in March 2025

The US FDA New Drug Approvals in March 2025

Disease of the Month – Dry age-related macular degeneration (dAMD)

Contact US

OUR INFORMATION

FOLLOW US